非感染性葡萄膜炎生物制剂与常规治疗的五年全身并发症风险比较
这项多中心回顾性队列研究基于TriNetX网络,比较了成人非感染性葡萄膜炎患者使用生物制剂与常规治疗的5年全身并发症风险。经倾向评分匹配后,与无全身治疗相比,生物制剂与严重感染和血液学细胞减少风险升高相关;与常规免疫调节治疗相比,生物制剂5年安全性总体相当,但血液学细胞减少、精神疾病和住院风险略高。
要点
- 与无全身治疗相比,生物制剂增加严重感染和血液学细胞减少风险。
- 与常规免疫调节治疗相比,生物制剂5年安全性总体相当。
- 生物制剂组血液学细胞减少、精神疾病和住院风险略高于常规治疗。
核心结论
- 在非感染性葡萄膜炎患者中,全身生物制剂治疗与无全身治疗相比严重感染和血液学细胞减少风险更高。
- 生物制剂与常规免疫调节治疗相比5年安全性总体相当,但血液学细胞减少、精神疾病和住院风险略高。
研究设计与样本
- 多中心回顾性临床队列研究,纳入TriNetX协作网络成人非感染性葡萄膜炎患者。
- 倾向评分匹配比较生物制剂与无全身治疗(各n=6896)及生物制剂与常规治疗(各n=5994)。
- 预设亚组分析比较生物制剂联合常规治疗与常规治疗单用(各n=3653)。
- 采用时间至事件分析评估全身并发症发生率。
主要发现
- 与无全身治疗相比,生物制剂组肺炎风险比为1.41(95%CI 1.20-1.67),脓毒症为1.43(95%CI 1.16-1.77),血液学细胞减少为1.58(95%CI 1.44-1.74)。
- 生物制剂组5年Kaplan-Meier估计累积发生率:肺炎6.43%,脓毒症3.87%,血液学细胞减少30.12%。
- 与无全身治疗相比,心力衰竭、血栓栓塞事件、精神疾病、糖尿病和全因死亡率无显著差异。
- 与常规免疫调节治疗相比,生物制剂组血液学细胞减少风险比为1.28(95%CI 1.16-1.41),精神疾病为1.13(95%CI 1.01-1.27),住院为1.20(95%CI 1.07-1.35)。
临床怎么用
- 支持指南一致的阶梯式免疫抑制治疗策略。
- 对需要全身治疗的患者进行个体化风险评估。
- 加强感染监测和血液学监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare 5-year systemic complication risks in noninfectious uveitis (NIU) patients treated with systemic biologic versus conventional therapy. DESIGN: Multicenter, retrospective clinical cohort study. PARTICIPANTS: Adult patients (≥18 years old) with NIU from the TriNetX Collaborative Network. METHODS: We identified patients with NIU. We assembled propensity score-matched comparisons: biologic therapy versus no systemic therapy (n = 6896 each) and biologic versus conventional therapy with corticosteroids matched (n = 5994 each) between January 1, 2005, and January 1, 2024. A prespecified subgroup analysis of Analysis 2 restricted to patients receiving combination biologic + conventional therapy versus conventional therapy alone (n = 3653 each) was also conducted. We used time-to-event analyses to identify incidence of systemic complications. MAIN OUTCOME MEASURES: Incidence of serious infections, hematologic cytopenias, heart failure, thromboembolic events, diabetes mellitus, malignancy, psychiatric illness, all-cause hospitalization, and all-cause mortality. RESULTS: After propensity score matching, cohorts were balanced on all measured covariates (all standardized mean differences [SMDs] <0.1). Compared with no systemic therapy, biologic treatment was associated with higher 5-year risks of serious infections, including pneumonia (hazard ratio [HR], 1.41, 95% confidence interval [CI], 1.20-1.67), sepsis (HR, 1.43, 95% CI, 1.16-1.77), and hematologic cytopenias (HR, 1.58, 95% CI, 1.44-1.74), representing 5-year Kaplan-Meier-estimated cumulative incidences of 6.43%, 3.87%, and 30.12%, respectively, in biologic-treated patients. Risks of heart failure, thromboembolic events, psychiatric illness, diabetes, and all-cause mortality did not significantly differ between groups. When compared with conventional immunomodulatory therapy, biologic treatment demonstrated a largely comparable 5-year safety profile, with the primary exceptions of higher rates of hematologic cytopenias (HR, 1.28, 95% CI, 1.16-1.41), psychiatric illness (HR, 1.13, 95% CI, 1.01-1.27), and hospitalization (HR, 1.20, 95% CI, 1.07-1.35). CONCLUSIONS: In patients with NIU, systemic biologic therapy was associated with higher risks of serious infections and hematologic cytopenias compared with no systemic treatment, while demonstrating a 5-year safety profile broadly comparable to conventional immunomodulatory therapy. These findings support guideline-concordant stepwise immunosuppression and underscore the importance of individualized risk assessment, infection surveillance, and hematologic monitoring for patients requiring systemic therapy. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Chauhan MZ, Muayad J, Surgent-Nahay JL, et al. Comparative Five-Year Risks of Systemic Complications with Biologic versus Conventional Therapy in Noninfectious Uveitis. Ophthalmology. 2026. PMID: 42409178. doi:10.1016/j.ophtha.2026.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。